BLAINJECTIONINJECTABLE
Approved
Nov 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
44
Data completeness
7/8 — Comprehensive
FASENRA (benralizumab) by AstraZeneca is interleukin 5 receptor alpha-directed antibody interactions [moa]. Approved for interleukin-5 receptor alpha-directed cytolytic antibody [epc]. First approved in 2017.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FASENRA (benralizumab) is a monoclonal antibody that targets the interleukin-5 receptor alpha, designed to reduce eosinophil levels in patients with eosinophilic asthma. It is administered via subcutaneous injection and works by directing cytolytic activity against IL-5 receptor-expressing cells. This mechanism addresses the underlying inflammatory pathway in severe eosinophilic asthma.
$0.069BPart D
PeakProduct is at peak commercial maturity with 11,680 annual Part D claims; commercial teams are optimizing market share against established competitors in a moderate-competition environment.
Mechanism of Action
Interleukin 5 Receptor alpha-directed Antibody Interactions
Pharmacologic Class:
Interleukin-5 Receptor alpha-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (44)
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
Started Jul 2026
230 enrolled
AsthmaEosinophilic Granulomatosis With Polyangiitis (EGPA)Hypereosinophilic Syndrome (HES)
Fasenra: An Asthma Study
Started Jul 2026
40 enrolled
Eosinophilic AsthmaSevere AsthmaSevere Eosinophilic Asthma+1 more
A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
Started Dec 2025
335 enrolled
Severe Eosinophilic Asthma
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
Started Jul 2025
1,000 enrolled
Chronic Obstructive Pulmonary Disease
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
Started Apr 2025
14 enrolled
Eosinophilic Granulomatosis With Polyangiitis (EGPA)Hypereosinophilia Syndrome (HES)
Worked on FASENRA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.